GRAL
Revenue’s doing the heavy lifting
GRAIL kicked off 2026 with a pretty solid flex: Galleri revenue climbed 37% year over year to $39.8 million, and test volume rose 50% to more than 56,000. In other words, the cancer-detection test is getting more real-world traction, and that’s the kind of metric investors tend to care about when a company is still proving out its commercial engine.
The Epic move is the real elbow bump
The company also said it plans to integrate Galleri into the Epic electronic health record platform. That matters because Epic is the plumbing of modern healthcare — if you can get into that system, you’re suddenly a lot closer to doctors actually ordering your test without a bunch of extra friction. Translation: access could get easier, and easier access usually means better adoption.
More data, more hope, more conference season drama
GRAIL said new data from the NHS-Galleri trial and PATHFINDER 2 study will be presented at the 2026 American Society of Clinical Oncology annual meeting. That’s useful for two reasons:
- It gives investors more evidence to chew on about whether the test is gaining clinical credibility.
- It keeps GRAIL in the spotlight during one of the biggest cancer-research soapboxes of the year.
Big picture
GRAIL is still very much in the “show me” phase, but the combination of faster revenue growth, rising test volume, and a planned Epic integration suggests the company is making a stronger case that Galleri can become more than just a cool science project. For investors, that’s the kind of progress that can move the needle — even if the road to routine adoption is still long and bumpy.